Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Company FUSE-AI GmbH and T-Systems Switzerland

Xlife Sciences AG / Key word(s): Alliance/Contract Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Company FUSE-AI GmbH and T-Systems Switzerland 03.04.2024 / 17:00 CET/CEST Xlife Sciences is pleased to announce a collaboration between its portfolio company, FUSE-AI, and T-Systems Switzerland. This cooperation marks an important milestone in the distribution of the AI-powered software «Prostate.Carcinoma.ai» for radiology.

T-Systems Switzerland, as a subsidiary of T-Systems International GmbH, is considered a system-relevant IT and digitalization partner in the healthcare sector in Switzerland. Through this cooperation, T-Systems Switzerland distributes the AI-based solution for prostate analysis from FUSE-AI centrally in Switzerland, thereby enabling the commercialization of «Prostate.Carcinoma.ai» for radiological clinics and practices.

The software represents a significant timesaving of approximately 30 percent compared to the otherwise manual analysis of MRI image series in radiological applications, leading to increased efficiency and considerable financial benefits for clinics and practices. In addition to time savings, it is the goal of FUSE-AI to reduce the current rate of misdiagnoses in MRI examinations from 14% to 1%.

Oliver R. Baumann, CEO of Xlife Sciences, comments on the partnership as follows: «The collaboration between FUSE-AI and T-Systems in Switzerland is an example of successfully bridging groundbreaking research and market-leading application in healthcare. The AI-powered software «Prostate.Carcinoma.ai» represents exactly the kind of forward-looking technology that we at Xlife Sciences want to promote and bring to market maturity. It underscores our commitment to bringing innovative solutions to the healthcare market that not only improve patient care but also make the clinic routine more efficient.»